Board of Directors
Dr Lynn Drummond
Lynn Drummond joined Venture Life as non-executive chair in November 2013. Lynn has been Non-Executive Chairman of Infirst Healthcare Limited since early 2013 and is also a non-executive director of RPC Group plc, Shield Therapeutics Limited and Iron Therapeutic Holding AG. Previously Lynn spent 16 years at Rothschild in London most recently as a Managing Director within the investment banking division, with a particular focus on transactions within the healthcare sector. Prior to Rothschild, Lynn worked in the Cabinet Office in London as Private Secretary to the Chief Scientific Advisor.
Lynn holds a Bachelor of Science Degree in Chemistry from the University of Glasgow and a PhD in Biochemistry from the University of London. She is also a Fellow of the Royal Society of Chemistry and a Fellow of the Royal Society of Edinburgh.
Lynn chairs the Nomination Committee and is a member of the Audit Committee and Remuneration Committee.
Chief Executive Officer
Jerry Randall co-founded Venture Life in 2010 and is the Group’s Chief Executive Officer. From 2000 to 2009, Jerry was CFO of Sinclair Pharma plc, an international speciality pharma business, now listed on the main market in London. Sinclair was founded in August 2000 when Jerry completed the management buy-in with Dr Michael Flynn.
Jerry enjoyed a career initially in corporate finance and was involved in buy-ins and acted as advisor to both private and quoted companies between 1993 and 2000, in capacities as nominated advisor and in practice with KPMG. Jerry has been involved in a number of flotations and transactions on the Official List, Unlisted Securities Market and AIM, as well as raising private equity. He qualified as a chartered accountant with KPMG in 1990.
Chief Commercial Officer
Sharon Collins co-founded Venture Life in 2010 with Jerry Randall, and is the Chief Commercial Officer.
Sharon has almost 20 years experience within the healthcare industry, predominately in marketing, international sales and business development roles. She worked for a leading dental manufacturer for eight years and launched many products during this time.
Sharon worked for Sinclair Pharmaceuticals for five years within the International Business Development field and successfully completed more than 35 international out-licensing deals during a two year period. She qualified from Lancaster University in 1996 with a degree in Marketing and gained her MBA (with Distinction) in 2003.
Chief Manufacturing Officer
Gianluca joined the Board on 24 March 2014 following the acquisition by Venture Life of Biokosmes, the company he founded.
Gianluca began this career working in his father’s pharmacy, and then,after he graduated as a pharmacist,continued working for several years in the Milano University cosmetic Research and Development department researching cosmetic applications for raw materials used in different fields. In 1990 he started developing formulations for Italian cosmetic brands mainly in the perfumery and pharmacy area and started his own contract manufacturing business, Biokosmes. In 1999 Biokosmes started developing and manufacturing medical devices, selling predominantly in Europe. In 2002 Biokosmes passed its first FDA inspection, and started exporting its products to the US.
John Sylvester joined the Venture Life board as Non-Executive Director in November 2013. John is currently Chief Commercial Officer for Intervetional Medicine at BTG plc, having joined BTG in January 2011 following the £177 million acquisition of Biocompatibles by BTG. John joined Biocompatibles in 2005, taking responsibility for Marketing, Sales and Business Development, and was appointed to the Board as an executive director in the same year. His career covers a series of senior commercial roles for Rio Tinto Zinc plc, ICI plc and English China Clays plc where he was Managing Director prior to the acquisition by Imetal for £756 million.
Immediately before Biocompatibles John was with Baxter Healthcare working out of their European HQ in Zurich where he was VP Marketing for their European Medication delivery business, a $750m portfolio spanning both drugs and medical devices.
John chairs the Remuneration Committee and is a member of the Audit and Risk Committee and the Nomination Committee.
Peter Bream joined Venture Life in February 2016. Currently the Group Finance Director of Alcontrol Laboratories, Peter has over 20 years in international business including as a CFO of public companies in the pharmaceuticals, engineering, and chemical sectors.
Peter has a degree in Engineering and Management from Cambridge University and is a Chartered Accountant.
Peter chairs the Group’s Audit and Risk Committee and is a member of the Remuneration and Nomination Committees.
Chief Financial Officer
Adrian has significant financial management experience in the healthcare industry. Prior to joining Venture Life, he was Finance Director of Abbott Diabetes Care Ltd, a division of the US healthcare company, Abbott labs, and before this Group Finance Director at PAREXEL.
Previously, he served as Finance Director R&D at GSK and as Head of Business Planning & Analysis at Novartis Vaccines & Diagnostics. Before this he held senior financial management roles at Chiron corporation ( prior to acquisition by Novartis), and Powderject pharmaceuticals ( prior to acquisition by Chiron). Adrian completed his accountancy training at Andersen Consulting (now Accenture).
Adrian has a BAcc honours degree in accountancy from The University of Dundee and is a Chartered Management Accountant.